Company

Board of Directors

  • Michael Altman, CFA

    Senior Analyst, Perceptive Advisors

    Michael Altman joined Perceptive in 2007 and is a senior analyst on the investment team. His focus is on medical devices, diagnostics, digital health and specialty pharmaceuticals. He is also a member of the investment committee for the credit opportunities fund. Prior to Perceptive he was a healthcare trader and analyst at First New York Securities. Michael graduated from the University of Vermont with a B.S. in Business Administration. Michael serves on the board of directors for Vensun Pharmaceuticals and Vitruvius Therapeutics.

    Michael Altman joined Perceptive in 2007 and is a senior analyst on the investment team. His focus is on medical devices, diagnostics, digital health and specialty pharmaceuticals. He is also a member of the investment committee for the credit opportunities fund. Prior to Perceptive he was a healthcare trader and analyst at First New York Securities. Michael graduated from the University of Vermont with a B.S. in Business Administration. Michael serves on the board of directors for Vensun Pharmaceuticals and Vitruvius Therapeutics.

  • Robert Langer, D.Sc.

    David H. Koch Institute Professor, Massachusetts Institute of Technology, Co-Founder

    Robert S. Langer is one of 14 Institute Professors (the highest honor awarded to a faculty member) at the Massachusetts Institute of Technology (MIT). Dr. Langer has written approximately 1,130 articles. He also has approximately 800 issued and pending patents worldwide. Dr. Langer’s patents have been licensed or sublicensed to more than 250 pharmaceutical, chemical, biotechnology and medical device companies. He is the most cited engineer in history. He served as a member of the U.S. FDA’s SCIENCE Board, the agency’s highest advisory board, from 1995-2002, and as its chairman from 1999-2002. Dr. Langer has received more than 200 major awards including the 2006 United States National Medal of Science; the Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers; and the 2008 Millennium Prize, the world’s largest technology prize. He is the only engineer to receive the Gairdner Foundation International Award. Among his multiple accolades, Forbes Magazine selected Dr. Langer as "one of the 15 innovators worldwide who will reinvent our future."

    Robert S. Langer is one of 14 Institute Professors (the highest honor awarded to a faculty member) at the Massachusetts Institute of Technology (MIT). Dr. Langer has written approximately 1,130 articles. He also has approximately 800 issued and pending patents worldwide. Dr. Langer’s patents have been licensed or sublicensed to more than 250 pharmaceutical, chemical, biotechnology and medical device companies. He is the most cited engineer in history. He served as a member of the U.S. FDA’s SCIENCE Board, the agency’s highest advisory board, from 1995-2002, and as its chairman from 1999-2002. Dr. Langer has received more than 200 major awards including the 2006 United States National Medal of Science; the Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers; and the 2008 Millennium Prize, the world’s largest technology prize. He is the only engineer to receive the Gairdner Foundation International Award. Among his multiple accolades, Forbes Magazine selected Dr. Langer as "one of the 15 innovators worldwide who will reinvent our future."

  • Carmichael Roberts, Ph.D.

    General Partner, North Bridge Venture Partners, Co-Founder

    Carmichael Roberts joined North Bridge Venture Partners in 2007, where he focuses mainly on early-stage companies that make products using unique chemistry and materials inventions. Prior to North Bridge, Dr. Roberts co-founded and served as the president and chief executive officer of Arsenal Medical. Dr. Roberts has co-founded other ventures, including several focused on life sciences. In 1999, Dr. Roberts was named one of the world’s top 100 young entrepreneurs by MIT’s Technology Review. Prior to his entrepreneurial career, Dr. Roberts worked in business development at GelTex Pharmaceuticals, which was acquired by Genzyme for $1.1 billion, and in new product and business development at Dow Chemical (formerly Union Carbide Corporation). Dr. Roberts received his B.S. and Ph.D. in organic chemistry from Duke University, and he completed his postdoctoral National Science Foundation fellowship at Harvard University. Dr. Roberts also holds an M.B.A. from the MIT Sloan School of Management. He serves as an advisor for MIT’s Deshpande Center for Technological Innovation, Harvard’s Nanoscale Science and Engineering Center and the schools of Science and Engineering at Duke University.

    Carmichael Roberts joined North Bridge Venture Partners in 2007, where he focuses mainly on early-stage companies that make products using unique chemistry and materials inventions. Prior to North Bridge, Dr. Roberts co-founded and served as the president and chief executive officer of Arsenal Medical. Dr. Roberts has co-founded other ventures, including several focused on life sciences. In 1999, Dr. Roberts was named one of the world’s top 100 young entrepreneurs by MIT’s Technology Review. Prior to his entrepreneurial career, Dr. Roberts worked in business development at GelTex Pharmaceuticals, which was acquired by Genzyme for $1.1 billion, and in new product and business development at Dow Chemical (formerly Union Carbide Corporation). Dr. Roberts received his B.S. and Ph.D. in organic chemistry from Duke University, and he completed his postdoctoral National Science Foundation fellowship at Harvard University. Dr. Roberts also holds an M.B.A. from the MIT Sloan School of Management. He serves as an advisor for MIT’s Deshpande Center for Technological Innovation, Harvard’s Nanoscale Science and Engineering Center and the schools of Science and Engineering at Duke University.

  • Maria Palasis, Ph.D.

    President and Chief Executive Officer

    Maria Palasis is an industry veteran in merging material science and drug-delivery innovation to create best-in-class therapies for patients. She brings nearly 25 years of healthcare industry experience to Lyra. A repeat entrepreneur, her transformative leadership as CEO of 480 Biomedical and CEO and Chief Technology Officer of Arsenal Medical resulted in >$160 million of external and non-dilutive funding and the advancement of multiple programs into the clinic. Earlier in her career, she managed a portfolio of external biotech and medical device investments at Boston Scientific and led the development of several combination therapies. She is an inventor on more than 120 issued and pending patents. Maria received her B.S. and Ph.D. in Chemical Engineering from the University of Cincinnati, and she held a postdoctoral fellowship in molecular biology at the University of Cincinnati School of Medicine.

    Maria Palasis is an industry veteran in merging material science and drug-delivery innovation to create best-in-class therapies for patients. She brings nearly 25 years of healthcare industry experience to Lyra. A repeat entrepreneur, her transformative leadership as CEO of 480 Biomedical and CEO and Chief Technology Officer of Arsenal Medical resulted in >$160 million of external and non-dilutive funding and the advancement of multiple programs into the clinic. Earlier in her career, she managed a portfolio of external biotech and medical device investments at Boston Scientific and led the development of several combination therapies. She is an inventor on more than 120 issued and pending patents. Maria received her B.S. and Ph.D. in Chemical Engineering from the University of Cincinnati, and she held a postdoctoral fellowship in molecular biology at the University of Cincinnati School of Medicine.